BRCA1 and neoplasm: Since BRCA1/BRCA2 tumor testing can detect simultaneously both somatic and germline variants, with the exception of some variants like rearrangements, a higher number of patients who may benefit from PARPi can be identified at a faster turnaround time and at a lower cost (9).